Researchers found that by dosing study participants with a weakened, early developmental form of the parasite responsible for transferring malaria, they could trigger immunity to the disease for as much as a year in adults. Previous studies reported malaria vaccine effectiveness lasting for at least a few weeks.
“These results are really important,” Kirsten E. Lyke, MD, a researcher at the University of Maryland School of Medicine in Baltimore, said in a statement. “Malaria has such a devastating effect on children, especially in Africa. This vaccine has the potential to help travelers, military personnel and children in malaria-endemic areas.”
After being inoculated, participants were bitten by mosquitoes carrying the full-blown version of the same strain of parasite used in the vaccine. Overall, more than half of the participants who received a vaccine and were subsequently bitten were protected from developing malaria for up to a year. The protected participants were also unable to transmit the disease during that time.
The results of the Phase 1 trial are published in Nature Medicine.
More articles on vaccines:
Physician access to vaccine records linked to higher immunization rates
Flu vaccine produces better outcomes when administered in the morning
Zika vaccine testing could begin in September
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
